LeaderPortfolio
Rothbaum
Wayne Rothbaum
Rank #1425
UNITED STATESFinance & InvestmentsBiotech investing

Wayne Rothbaum

Net Worth
$2.917B
-0.1% (24h)
Wayne Rothbaum is a highly successful biotech investor and founder of Quogue Capital, an investment firm he launched in 2001. Rothbaum, age 58, has built a substantial fortune through strategic investments in the healthcare sector, particularly in biotech. His career includes founding and co-founding several cancer drug firms such as Acerta Pharma, Kartos Therapeutics, and Telios Pharma. He is also a board member and the largest shareholder of Iovance Biotherapeutics. Rothbaum's achievements are chronicled in the book "For Blood and Money: Billionaires, Biotech and the Quest for a Blockbuster Drug."

How to read Wayne Rothbaum's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Wayne Rothbaum, we anchor the narrative to Biotech investing and Biotech investing, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $2.917B alongside global rank #1425, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (UNITED STATES) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Education

Wayne Rothbaum was born on February 17, 1968, and is currently 58 years old. He earned a Bachelor of Arts/Science from the State University of New York at Binghamton and a Master of Arts in international economics from The George Washington University.

Rise to Success

Rothbaum began his career at The Carson Group, where he managed the life sciences practice and a boutique investment bank. In 2001, he founded Quogue Capital, a single-family office private equity fund that focuses on supporting small to mid-cap life sciences companies.

Rothbaum's investment strategy led him to become a prominent figure in biotech investing. His backing of Acerta Pharma, a cancer drug developer, is considered one of the greatest biotech investments of all time. He co-founded Acerta Pharma in 2012, serving as its executive chairman. In 2016, AstraZeneca acquired 55% of Acerta Pharma, and the remaining portion was acquired between 2022 and 2024. Rothbaum is also the executive chair of Kartos Therapeutics and Telios Pharma, both focused on cancer drug development. Rothbaum also led a restructuring of Iovance Biotherapeutics, where he is a board member and the largest shareholder, with a 9% stake.

Key Business Strategies

Rothbaum deploys his own funds for investments, emphasizing his personal conviction and expertise in the biotech field. His strategies include identifying and investing in innovative companies developing cancer therapies. He focuses on long-term value creation by supporting the growth of these companies and contributing to the advancement of medical treatments. Rothbaum's hands-on approach involves taking leadership roles within the companies he invests in, as seen with Iovance Biotherapeutics.

Philanthropy

Rothbaum has donated $300 million to SUNY Binghamton for a sports complex and scholarships, as well as to Ohio State University to build housing for cancer patients.

Career Timeline

2019

Cofounded Telios Pharma

Cofounded a firm focused on targeted therapy for blood cancers and ophthalmology diseases.

2016

Cofounded Kartos Therapeutics

Cofounded a cancer drug firm.

2012

Cofounded Acerta Pharma

Cofounded and became the largest investor in a cancer drug developer.

2001

Founded Quogue Capital

Established an investment firm focused on life sciences.

Philanthropic Impact

Education$300M

SUNY Binghamton Donation

Donated for a sports complex and scholarships.

Healthcare$300M

Ohio State University Donation

Donated to build housing for cancer patients.

Key Business Ventures & Holdings

CompanyStakeValue
Iovance Biotherapeutics9.00%$0.106M

Net Worth History

In-Depth Analysis

Early Life and Education

Wayne Rothbaum was born on February 17, 1968, and is currently 58 years old. He earned a Bachelor of Arts/Science from the State University of New York at Binghamton and a Master of Arts in international economics from The George Washington University.

Rise to Success

Rothbaum began his career at The Carson Group, where he managed the life sciences practice and a boutique investment bank. In 2001, he founded Quogue Capital, a single-family office private equity fund that focuses on supporting small to mid-cap life sciences companies.

Rothbaum's investment strategy led him to become a prominent figure in biotech investing. His backing of Acerta Pharma, a cancer drug developer, is considered one of the greatest biotech investments of all time. He co-founded Acerta Pharma in 2012, serving as its executive chairman. In 2016, AstraZeneca acquired 55% of Acerta Pharma, and the remaining portion was acquired between 2022 and 2024. Rothbaum is also the executive chair of Kartos Therapeutics and Telios Pharma, both focused on cancer drug development. Rothbaum also led a restructuring of Iovance Biotherapeutics, where he is a board member and the largest shareholder, with a 9% stake.

Key Business Strategies

Rothbaum deploys his own funds for investments, emphasizing his personal conviction and expertise in the biotech field. His strategies include identifying and investing in innovative companies developing cancer therapies. He focuses on long-term value creation by supporting the growth of these companies and contributing to the advancement of medical treatments. Rothbaum's hands-on approach involves taking leadership roles within the companies he invests in, as seen with Iovance Biotherapeutics.

Philanthropy

Rothbaum has donated $300 million to SUNY Binghamton for a sports complex and scholarships, as well as to Ohio State University to build housing for cancer patients.

Data Sources & Methodology

Figures for Wayne Rothbaum are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.